Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 North Carolina-based life ... M.D., Professor of Medicine, Mayo Clinic College of ... of Directors. , Entegrion’s Executive Chairman ... to have Dr. Noel, a distinguished physician and ... join Entegrion’s Board. His expertise in hematology and ...
(Date:3/5/2015)... 2015  UBM Medica US announces that ... community to help oncologists and other clinicians gain ... regarding the use of targeted therapies and immunotherapies, ... March is National Kidney Cancer Awareness Month ... treatment options for renal cell carcinoma (RCC) patients. ...
(Date:3/5/2015)... -- In response to the incorrect assertions by LD, distributed ... on February 12, 2015. Impeto Medical SAS and its ... their SUDOSCAN® devices have been proven to provide accurate ... have the courts decide this dispute rather than the ... written by Key Opinion Leaders, published by significant peer-reviewed ...
(Date:3/5/2015)... Cleveleys (UK) (PRWEB) March 05, 2015 ... implantable polymer have received the CE mark (European) approval. ... the European Free Trade Association (EFTA) and the European ... mark has now been granted to implants supplied by ... disc spinal conditions. , Osimplant's Cervical Expandable Bladed ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3
... May 20 InspireMD, Ltd. announced today,the completion ... Acute,Myocardial). The trial was designed to confirm the ... during Primary PCI in STEMI,patients. , ... prospective, single arm, 60 patients,study (Principal investigator: Dr. ...
... Sky One Medical,Inc. ("China Sky One Medical" or ... leading,fully integrated pharmaceutical company in the People,s Republic ... agreement with Taiwan Golden,Biotechnology Corporation to begin cooperating ... Antroquinonol. , Golden Biotechnology ...
... Hawaii, has just installed the trailblazing new Hydrologix Grease ... brown grease waste into clear water - right in ... and "green" service is a business smart decision in ... reduces the need to pump and haul away the ...
Cached Biology Technology:InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 2InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le 3China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 2China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug 3Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 2Marriott Resort Magically Turns Brown Grease "Green" With The Cost-Cutting Hydrologix GRS 3
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
(Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... work involving 2,700 researchers from 80 countries, the world,s scientists ... Census of Marine Life, which provides the first in-depth look ... The Census of Marine Life initiative, started in 2000, is ... , the result of more than 540 expeditions and 9,000 days ...
... oil long encouraged by doctors as a supplement to ... severe colitis and colon cancer in mice in research led ... journal Cancer Research . Jenifer Fenton, a food ... that supports establishing a dose limit for docosahexaenoic acid (DHA), ...
... congratulates Cambridge scientist and Editor Emeritus of Reproductive ... been awarded with the 2010 Nobel Prize in Medicine ... that has helped millions of infertile couples worldwide to ... a procedure in which egg cells are fertilised outside ...
Cached Biology News:San Diego Supercomputer Center participates in first 'Census of Marine Life' 2Fish oil linked to increased risk of colon cancer in mice 2Nobel Prize for Professor Robert G. Edwards, Editor Emeritus of Reproductive BioMedicine Online 2
UBC13 Antibody...
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... (Thr183/Tyr185) Antibody, Catalog #9251, 200 ul ... 200 ul SAPK/JNK Cell Extracts, Catalog ... HRP-linked Antibody, Catalog #7074, 100 ul ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Biology Products: